SNAC is redefining Phase 2-4 clinical trials of emerging remyelinating therapies for Multiple Sclerosis (MS) with a multimodal turnkey central reading solution. We offer a full suite of regulatory-compliant imaging-related service tailored to meet..
Relevance: 16.640915